England adds five conditions to community pharmacy treatment programme

Pharmacies take on five more care pathways

Community pharmacies in England will begin treating five additional common conditions without requiring patients to see a general practitioner first. BBC News reported on September 10 that the autumn expansion covers low-frequency migraine in adults, mild-to-moderate acne, mild skin infections and scabies, adult ear infections, and hay fever or allergic rhinitis in children. The additions bring the programme's total to 12 clinical pathways.

Pharmacists already provide treatment under Pharmacy First for sore throat, sinusitis, earache, infected insect bites, impetigo, shingles and uncomplicated urinary tract infections. A few hundred pharmacies will initially deliver the new pathways, followed by a gradual expansion to thousands of NHS community pharmacies. Patients may arrive directly or be referred through a GP practice or the NHS 111 service.

Part of a wider shift from hospitals to communities

The change is designed to shorten access routes for routine treatment and reduce pressure on GP appointments and emergency departments. The government's 2026-27 community-pharmacy framework had already scheduled a national independent-prescribing offer for autumn 2026, including as many as five new prescribing-only pathways. It increased the sector's annual funding envelope and established infrastructure and consultation payments for participating contractors.

The expansion follows substantial use of the original programme. A government announcement in May said Pharmacy First delivered more than 3.3 million consultations between March 2025 and February 2026, 43% more than in the preceding comparable period. BBC reporting cited a later cumulative figure of 14 million consultations and noted especially heavy use for sore throats and urinary infections. The two figures cover different reporting periods and should not be treated as contradictory.

Capacity will determine the rollout's reach

Patient groups welcomed easier migraine access, but pharmacy representatives cautioned that the network remains under financial pressure. Expanding the list of treatable conditions does not ensure that every branch can immediately provide every service. Pharmacies need qualified prescribers, compatible electronic systems, clinical protocols and enough staff time to perform assessments safely while maintaining dispensing work.

The main question is therefore implementation rather than authorisation. Officials will need to publish pathway criteria, confirm which pharmacies are ready, monitor referrals to doctors for complicated cases and measure whether the programme actually reduces pressure elsewhere in the NHS. For patients, the immediate change is a new first point of contact for five specified conditions. For the health system, it is a test of whether funded independent prescribing can turn high-street pharmacies into a durable part of England's primary-care infrastructure.